ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Chung, Carmen [1 ]
Jiang, Haiyan [2 ]
Isaranuwatchai, Wanrudee
Di Maio, Mas-Simo [3 ]
Lau, Anthea [2 ]
Hoch, Jeffrey
Feld, Ronald [2 ]
Tsao, Ming-Sound [4 ]
Gridelli, Cesare [5 ]
Gallo, Ciro [6 ]
Ciardiello, Fortunato [6 ]
Butts, Charles A. [7 ]
Perrone, Francesco [3 ]
Leighl, Natasha B. [8 ]
机构：
[1] Univ Toronto, Toronto, ON M5S 1A1, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Natl Canc Inst, Milan, Italy
[4] Princess Margaret Hosp, Toronto, ON, Canada
[5] Sg Moscati Hosp, Avellino, Italy
[6] Univ Naples 2, Naples, Italy
[7] Cross Canc Inst, Edmonton, AB, Canada
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cisplatin and gemcitabine; erlotinib; advanced non-small cell lung cancer; economic analysis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-020
引用
收藏
页码：S602 / S603
页数：2
相关论文
共 50 条
  • [41] Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis.
    Pappagallo, G. L.
    Belvedere, O.
    Vinante, O.
    Grossi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 398S - 398S
  • [42] Gemcitabine plus cisplatin in advanced non small cell lung cancer (NSCLC)
    Casal, J
    Huidobro, G
    Grande, C
    ANNALS OF ONCOLOGY, 1998, 9 : 103 - 103
  • [43] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [44] Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
    Scaqliotti, G.
    Park, K.
    Patil, S.
    Rolski, J.
    Gorksel, T.
    Gans, S. J. M.
    Martins, R.
    Visseren-Grul, C.
    Peterson, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 363 - 363
  • [45] Randomized phase III study of Gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer (NSCLC)
    Scagliotti, G
    Crino, L
    Conte, PF
    Rinaldi, M
    De Marinis, F
    Gridelli, C
    ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
  • [46] International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial
    Gridelli, C.
    Ciardiello, F.
    Feld, R.
    Butts, C. A.
    Gebbia, V.
    Genestreti, G.
    Favaretto, A. G.
    Wierzbicki, R.
    Gallo, C.
    Perrone, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients
    Grigorescu, A. C.
    Bala, C.
    JOURNAL OF BUON, 2013, 18 (01): : 188 - 194
  • [48] Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
    Chen, Yi
    Li, Jinyu
    Chen, Shixue
    Zhang, Yibao
    Hu, Yi
    Zhang, Guoqing
    Yan, Xiang
    Jiao, Shunchang
    SCIENTIFIC REPORTS, 2017, 7
  • [49] ERLOTINIB AS SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ECONOMIC MODELING (EM) RESULTS
    Santos, E. A., V
    Buschinelli, C. T.
    Ferracini, M.
    Pepe, C.
    Estanislao, M.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [50] Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
    Yi Chen
    Jinyu Li
    Shixue Chen
    Yibao Zhang
    Yi Hu
    Guoqing Zhang
    Xiang Yan
    Shunchang Jiao
    Scientific Reports, 7
12345